Initial Payment Period. Novartis’ obligation to pay Akcea the Novartis Royalty above with respect to a Product will continue on a country-by-country and Product-by-Product basis from the date of First Commercial Sale of such Product until the later of the date of expiration of (i) the [***], (ii) the [***], and (iii) the [***] (such royalty period, the “Initial Payment Period”). * ***Confidential Treatment Requested
Appears in 2 contracts
Sources: Strategic Collaboration, Option and License Agreement (Akcea Therapeutics, Inc.), Strategic Collaboration, Option and License Agreement (Akcea Therapeutics, Inc.)
Initial Payment Period. Novartis’ obligation to pay Akcea the Novartis Royalty above with respect to a Product will continue on a country-by-country and Product-by-Product basis from the date of First Commercial Sale of such Product until the later of the date of expiration of (i) the [***], (ii) the [***], and (iii) the [***] (such royalty period, the “Initial Payment Period”). * ***Confidential Treatment RequestedRequested 33
Appears in 1 contract
Sources: Collaboration and Option Agreement